After a successful 2017 for Relevium Technologies, we will look at all the accomplishments undertaken by management at RLV, as well we will note what investors should look forward to in 2018.
In June, Relevium announced their long and anticipated acquisition of BioGanix, a private nutraceutical company with $4.5 Million US in Revenue and 30% EBITDA. The purchase terms included $2.6M in Cash, $675,000 in cash, $675,000 payable in cash after 12 months and 2.1M in 2 year Convertible Notes. Since the acquisition of BioGanix, the team at Relevium have increased the sales of BioGanix products by over 50% and have reported revenues of over 700K in the first 50 days since its acquisition. That is equivalent to approximately $14,000 a day!
Since the announcement made on September 7th 2017, management completed the development of their Mach 2.0 Marketing Engine software program which will optimize marketing expenses, enhance pricing strategies and focus on product recommendation to its consumers. Relevium Technologies continues to look at how it can implement, acquire or build technology solutions to bring evolutions to the e-commerce market. We expect evolutions of Mach 2.0 as well add ons in 2018.
On September 28th 2017, Relevium entered into an agreement with Biodevas of France and Salvenia of Montréal to develop a nutraceutical brand of products aimed at the multibillion Pet Care industry. This is a partnership that will add revenues to the bottom line on the balance sheet and will not result in further dilution to shareholders. This is an update we will also be looking forward to as we enter 2018 as the company works hard to create new products for their launch during spring of 2018. These products will be a part of a wholly owned subsidiary of Relevium Technologies.
Hempco and PlanetHemp
On November 27th shareholders saw their stock rise to new highs as the company released updates on their anticipated partnership with Hempco. Relevium has entered into an exclusive product agreement for the sale of Hempco’s retail product called PlanetHemp. Relevium will sell PlanetHemp or a new brand through their online e-commerce platform in the US and the UK which could include Walmart, Amazon, Jet, Costco, Alibaba and more. This partnership will add significant revenue for Relevium without diluting shareholders. Hempco and Relevium Technologies will also work together to create additional Hemp and other CBD infused products to meet market demand.
Tersus Life Sciences Provinal Ultra-Purified Omega 7
Shareholders received additional value as RLV announced a new exclusive partnership with Tersus Life Sciences for the distribution of Provinal® Purified Omega 7 for both human and the pet sector. Dr. Tina Sampalis, Chief Science Officer at Terus Life Sciences and active board member of Relevium has been pinnacle in the partnership and development of Provinal and was also the pioneer behind the creation of Krill Oil while at Neptune Technologies (TSX: NEPT) Relevium will sell Provinal® based or infused products through its online distribution channels such as Amazon, Walmart, Jet and others for a 2 year term which is renewal-able on certain sales metrics.
Lowered Debt and Increased Cash
Relevium announced to shareholders that their cash position increased an additional $1.1 Million dollars through the exercise of warrants and the reduction of its long-term debt by $900,000 through the conversion of convertible debentures. These additional funds will assist Relevium to undertake further acquisitions in 2018 through possible all cash transactions. Having additional cash on hand and a stronger balance sheet is beneficial for shareholders as this will result in less dilution for acquisitions since purchases may be paid in cash. The balance sheet is stronger and more attractive in the event that further financing discussions are necessary to acquire a large target.Looking Forward to 2018
As we kick off the New Year, investors can expect to see developments on multiple partnerships including the launch of a wholly-owned subsidiary of Relevium for the launch of their pet nutraceutical line, sales of hemp and CBD infused products and sales of Provinal® based or infused products from Tersus Life Sciences. These non-dilutive partnerships will further add revenues for Relevium and will minimize the risk for shareholders. Management at Relevium has already proven to shareholders that they are committed to delivering on executing on their promise as they have accomplished many milestones in a short period of time. We look forward to the developments and value that Relevium will deliver to shareholders in the near term as they work diligently to increase shareholder value through additional acquisitions and increased revenues.
About Relevium Technologies Relevium is a publicly traded corporation strategically focused on the acquisition of entrepreneurial e-brands and technologies with your health and wellness in mind. Our area of interest and focus include Nutraceuticals, Sports Nutrition and Nutri-cosmeceuticals. Relevium creates shareholder value by aggregating entrepreneurial health and wellness e-brands through a shared success structure that allows investors to secure excellent value at source and while seeking enhanced valuations in the public capital markets.
Forward Looking Statements: This article may contain "forward-looking information" (as defined in applicable Canadian securities legislation) that is based on expectations, estimates and projections as of the date of the content is published on this website. Wherever possible, words such as "anticipate", "believe", "expects", "intend" and similar expressions have been used to identify these forward- looking statements. Information in this article has been furnished for your information only, is accurate at the time of posting, and may be superseded by more current information. Except as required by law, we do not undertake any obligation to update the information, whether as a result of new information, future events or otherwise. This article should not be considered as personal financial advice. Full disclosure: Equity Insight Inc. is a paid client of Relevium Technologies